Latest Insider Transactions at Pmv Pharmaceuticals, Inc. (PMVP)
This section provides a real-time view of insider transactions for Pmv Pharmaceuticals, Inc. (PMVP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PMV Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PMV Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2024
|
Deepika Jalota Chief Development Officer |
SELL
Open market or private sale
|
Direct |
7,218
-5.75%
|
$7,218
$1.5 P/Share
|
|
Sep 11
2024
|
Michael Carulli Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,891
-3.17%
|
$2,891
$1.5 P/Share
|
|
Jan 18
2024
|
Deepika Jalota Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
95,555
+43.23%
|
-
|
|
Jan 18
2024
|
David Henry Mack President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
163,890
+27.03%
|
-
|
|
Jan 18
2024
|
Michael Carulli Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,220
+47.39%
|
-
|
|
Nov 22
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
87,786
-100.0%
|
$175,572
$2.23 P/Share
|
|
Nov 10
2023
|
David Henry Mack President and CEO |
BUY
Bona fide gift
|
Indirect |
85,307
+34.04%
|
-
|
|
Nov 10
2023
|
David Henry Mack President and CEO |
SELL
Bona fide gift
|
Direct |
85,307
-23.44%
|
-
|
|
Oct 18
2023
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
198,407
+35.29%
|
$0
$0.53 P/Share
|
|
Sep 15
2023
|
Deepika Jalota Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,104
-12.05%
|
$24,624
$6.62 P/Share
|
|
Sep 15
2023
|
Leila Alland Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,291
-12.05%
|
$37,746
$6.62 P/Share
|
|
Aug 07
2023
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
85,500
+34.07%
|
$0
$0.53 P/Share
|
|
Nov 25
2022
|
Winston Kung COO, CFO |
SELL
Bona fide gift
|
Direct |
2,560
-19.45%
|
-
|
|
Sep 09
2022
|
Deepika Jalota Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,050
+50.0%
|
-
|
|
Sep 09
2022
|
Leila Alland Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,200
+50.0%
|
-
|
|
May 26
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
26,253
-23.02%
|
$393,795
$15.93 P/Share
|
|
Apr 27
2022
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,000
+29.21%
|
$0
$0.53 P/Share
|
|
Apr 20
2022
|
Winston Kung COO, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+27.4%
|
$12,000
$3.22 P/Share
|
|
Mar 31
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,500
-100.0%
|
$724,500
$21.17 P/Share
|
|
Mar 30
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
75,000
-68.49%
|
$1,650,000
$22.39 P/Share
|
|
Mar 29
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
365,000
-76.92%
|
$7,665,000
$21.52 P/Share
|
|
Mar 08
2022
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+29.86%
|
$20,000
$1.37 P/Share
|
|
Dec 30
2021
|
Winston Kung COO, CFO |
SELL
Bona fide gift
|
Direct |
2,725
-29.22%
|
-
|
|
Dec 15
2021
|
David Henry Mack President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+25.02%
|
$0
$0.53 P/Share
|
|
Dec 09
2021
|
David Henry Mack President and CEO |
BUY
Bona fide gift
|
Indirect |
40,000
+50.0%
|
-
|
|
Dec 09
2021
|
David Henry Mack President and CEO |
SELL
Bona fide gift
|
Indirect |
40,000
-17.55%
|
-
|
|
Oct 06
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
800
-0.07%
|
$24,000
$30.15 P/Share
|
|
Oct 04
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
100
-0.01%
|
$3,000
$30.08 P/Share
|
|
Oct 01
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
11,541
-1.04%
|
$346,230
$30.1 P/Share
|
|
Sep 30
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
2,978
-0.27%
|
$89,340
$30.03 P/Share
|
|
Sep 29
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
5,708
-0.51%
|
$171,240
$30.04 P/Share
|
|
Sep 27
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
1,753
-0.16%
|
$52,590
$30.11 P/Share
|
|
Sep 22
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
100
-0.01%
|
$3,000
$30.0 P/Share
|
|
Sep 22
2021
|
Arnold J Levine |
SELL
Open market or private sale
|
Direct |
3,500
-0.85%
|
$105,000
$30.0 P/Share
|
|
Sep 17
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
711
-0.06%
|
$21,330
$30.03 P/Share
|
|
Sep 13
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
13,272
-1.17%
|
$398,160
$30.2 P/Share
|
|
Sep 10
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
43,227
-1.84%
|
$1,296,810
$30.74 P/Share
|
|
Sep 09
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
14,329
-1.2%
|
$429,870
$30.31 P/Share
|
|
Sep 09
2021
|
Leila Alland Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100
-100.0%
|
$3,000
$30.25 P/Share
|
|
Sep 09
2021
|
Leila Alland Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+50.0%
|
$300
$3.9 P/Share
|
|
Sep 07
2021
|
Leila Alland Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,900
-100.0%
|
$117,000
$30.25 P/Share
|
|
Sep 07
2021
|
Leila Alland Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+50.0%
|
$11,700
$3.9 P/Share
|
|
Sep 02
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
5,400
-0.45%
|
$162,000
$30.15 P/Share
|
|
Sep 01
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
21,986
-1.8%
|
$659,580
$30.38 P/Share
|
|
Aug 31
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
19,520
-1.57%
|
$585,600
$30.12 P/Share
|
|
Aug 30
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
13,233
-1.05%
|
$396,990
$30.05 P/Share
|
|
Aug 27
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
24,442
-0.96%
|
$733,260
$30.78 P/Share
|
|
Aug 26
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
21,154
-0.82%
|
$634,620
$30.76 P/Share
|
|
Aug 25
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
13,526
-0.85%
|
$419,306
$31.01 P/Share
|
|
Aug 24
2021
|
Thilo Schroeder Director |
SELL
Open market or private sale
|
Indirect |
14,490
-0.9%
|
$449,190
$31.08 P/Share
|